Plain-English translation of NCT07597629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called combined with another drug (either HB1901 or ) to see if it can help people with advanced breast cancer that cannot be removed by surgery. Researchers want to understand how safe this combination is, how the body processes it, and whether it helps slow or shrink the cancer.
Advanced breast cancer that has spread or cannot be surgically removed is very difficult to treat, and patients often need new options after current treatments stop working. This trial exists to explore whether this medication combination might offer a new hope for people in this situation.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination by infusion during clinic visits, with each treatment cycle lasting 3 weeks. You will continue treatment until your cancer progresses, you experience side effects that are too difficult to manage, or you need to start a different cancer therapy. Throughout the trial, you'll have regular blood tests, scans, and check-ups to monitor how the treatment is working and how your body is responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Enrollment target
~36 participants
Started
May 2026
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trials Information Group officer
Affiliated Tumor Hospital of Harbin
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.